LabCorp Expands Access to LabCorp AccuDraw® to Support Better Patient Care
June 04 2015 - 8:45AM
Business Wire
Laboratory Corporation of America® Holdings (LabCorp®) (LH:
NYSE) today announced the expanded availability of its proprietary
specimen collection and handling software, LabCorp AccuDraw®, to
all clients through its website at www.LabCorp.com. Combining
on-screen visual cues with step-by-step tutorials, AccuDraw is an
innovative tool designed to guide the health care professional who
collects patient specimens throughout the specimen collection
process. AccuDraw helps to facilitate collection and appropriate
stabilization of the correct specimen type and sample volume. This
technology-enabled solution leads to fewer errors in specimen
collection and processing, a reduced chance of delays in testing,
and a lower likelihood of having a patient undergo a second visit
to a health care professional for further specimen collection.
AccuDraw has been used in LabCorp's patient service centers and by
LabCorp’s phlebotomists located in client locations for over five
years. AccuDraw has previously only been, and will continue to be,
available to LabCorp clients through the LabCorp Beacon®
application.
“As the world’s leading healthcare diagnostics company, LabCorp
is committed to developing technology-enabled solutions that change
the way care is provided and improve patient outcomes,” said David
P. King, Chairman and Chief Executive Officer of LabCorp. “Our
AccuDraw system has dramatically improved the patient experience,
ensuring accurate collections for tests for over 100 million
patient encounters. We are excited to expand customer access to
this successful tool.”
AccuDraw provides a detailed set of specimen collection and
handling instructions, allowing office staff to spend more time on
patient care and less time confirming the specimen collection
process and requirements. On-screen visual cues are combined with
detailed collection instructions to help ensure specimen and
collection accuracy in the physician office.
For patients and the physician office, AccuDraw provides:
- Improved precision and accuracy –
Visual cues are customized to the specific physician test order and
linked to LabCorp’s current test requirements.
- High-quality specimens – the guided
process and clear instructions helps to ensure the highest quality
specimen is sent to the laboratory for testing.
- Time efficiencies – Reduce the amount
of time spent speaking to the lab about specimen requirements or
identifying specimens that were not properly submitted to the
lab.
- Reduction in repeat draws – AccuDraw’s
collection, handling, and shipping guidance significantly reduces
the need for patient redraws and repeat visits.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through
LabCorp Diagnostics, and end-to-end drug development support
through Covance Drug Development. LabCorp is a pioneer in
commercializing new diagnostic technologies and is improving
people’s health by delivering the combination of world-class
diagnostics, drug development and knowledge services. With combined
revenue proforma for the Covance acquisition in excess of $8.5
billion in 2014 and more than 48,000 employees in over 60
countries, LabCorp offers innovative solutions to healthcare
stakeholders. LabCorp clients include physicians, patients and
consumers, biopharmaceutical companies, government agencies,
managed care organizations, hospitals, and clinical labs. To learn
more about Covance Drug Development, visit www.covance.com. To
learn more about LabCorp and LabCorp Diagnostics, visit
www.labcorp.com.
This press release contains forward-looking
statements including with respect to estimated 2015 guidance and
the impact of various factors on operating results. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive
actions in the marketplace, adverse actions of governmental and
other third-party payers and the results from the Company’s
acquisition of Covance. Actual results could differ materially from
those suggested by these forward-looking statements. Further
information on potential factors that could affect LabCorp’s
operating and financial results is included in the Company’s Form
10-K for the year ended December 31, 2014, including in each case
under the heading risk factors, and in the Company’s other filings
with the SEC, as well as in the risk factors included in Covance’s
filings with the SEC. The information in this press release should
be read in conjunction with a review of the Company’s filings with
the SEC including the information in the section of the Company’s
Form 10-K for the year ended December 31, 2014, subsequent Forms
10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150604005108/en/
Laboratory Corporation of America® HoldingsPaul Surdez,
336-436-5076www.labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024